These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12745131)

  • 1. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
    Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM;
    Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV; Burke TA; McCoy MA; Trotter JP
    Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
    Whelton A; White WB; Bello AE; Puma JA; Fort JG;
    Am J Cardiol; 2002 Nov; 90(9):959-63. PubMed ID: 12398962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
    Osterhaus JT; Burke TA; May C; Wentworth C; Whelton A; Bristol S
    Clin Ther; 2002 Jun; 24(6):969-89. PubMed ID: 12117086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F; Zhao S; Pettitt D
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Grover SA; Coupal L; Zowall H
    Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 12. Celecoxib- and rofecoxib-induced delirium.
    Macknight C; Rojas-Fernandez CH
    J Neuropsychiatry Clin Neurosci; 2001; 13(2):305-6. PubMed ID: 11449042
    [No Abstract]   [Full Text] [Related]  

  • 13. A side effect of COX-2 inhibitors.
    Harv Health Lett; 2003 Apr; 28(6):7. PubMed ID: 12777233
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib, rofecoxib, and acute temporary visual impairment.
    Coulter DM; Clark DW; Savage RL
    BMJ; 2003 Nov; 327(7425):1214-5. PubMed ID: 14630760
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.
    Epstein M
    Am J Ther; 2001; 8(2):81-3. PubMed ID: 11304661
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular events and COX-2 inhibitors.
    Fleming M
    JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract]   [Full Text] [Related]  

  • 18. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
    Blondon H
    Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
    [No Abstract]   [Full Text] [Related]  

  • 19. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M; Richard H; Pilote L
    BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.
    Budenholzer BR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12130617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.